[Federal Register Volume 85, Number 89 (Thursday, May 7, 2020)]
[Notices]
[Page 27248]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09701]
[[Page 27248]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-643]
Importer of Controlled Substances Application: Almac Clinical
Services Incorp. (ACSI)
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before June 8, 2020.
Such persons may also file a written request for a hearing on the
application on or before June 8, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2020, Almac Clinical Services Incorp.
(ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964, applied to be
registered as an importer of the following basic class(es) of a
controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Noroxymorphone....................... 9668 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
dosage form to conduct clinical trials.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-09701 Filed 5-6-20; 8:45 am]
BILLING CODE 4410-09-P